Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.